{
    "10.1016_j.drudis.2020.02.006.pdf": {
        "new materials": {
            "Yes/No": "No",
            "sentence": " The document does not mention the discovery of any new materials."
        },
        "screening algorithms": {
            "Yes/No": "No",
            "sentence": " The document does not mention any new or novel high-throughput or large-scale screening algorithm, methods or workflow."
        },
        "experimental methodology": {
            "Yes/No": "Yes",
            "sentence": " The putative druggable domains were identified using structural data and ligand desolvation, which indicates the use of computational algorithms to analyze protein structures.\n\nHowever, there is no mention of novel experimental methodology or specific screening algorithms used in the document."
        },
        "ML algorithms": {
            "Yes/No": "No",
            "sentence": " The document does not mention the development of any new machine learning and deep learning algorithm or AI model"
        },
        "models": {
            "Yes/No": "Yes",
            "sentence": " The compilation of druggable target classes could help strategize emerging efforts to systematically develop chemical reagents for the human proteome [9]."
        },
        "funding": {
            "Yes/No": "Yes",
            "sentence": " The SGC is a registered charity number 1097737 that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, etc."
        },
        "material datasets": {
            "Yes/No": "Yes",
            "sentence": " All 46 domains present in at least 20 human proteins and where median ligand desolvation upon binding is equal to or greater than that found in bromodomains are listed."
        },
        "drug formulations explored": {
            "Yes/No": "Yes",
            "sentence": " The document mentions exploring drug formulations in the sentence \"Notably, they can be incorporated in pharmaceutical formulations to enhance drug solubility, absorption, and bioavailability due to the formulation itself and the P-gp inhibitory effects of the excipients.\""
        },
        "novel drug formulations": {
            "Yes/No": "No",
            "sentence": " The SGC is a registered charity number 1097737 that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, etc."
        },
        "lead small-molecule drug candidates": {
            "Yes/No": "Yes",
            "sentence": " The Boehringer Ingelheim, Drug Discovery Today Volume 25, Number 3 March 2020 TABLE 2 Putative druggable domains in the human genomea Domain name Proteins in the human Median ligand Proteins desolvation with bound ligands in the PDB GPCR, rhodopsin-like 710 95 37 Protein kinase domain 482 90 195 WDR 266 77 4 ."
        },
        "clinical trials": {
            "Yes/No": "Yes",
            "sentence": " The document does not mention any specific clinical trials, but it is related to drug discovery and development, which implies the existence of ongoing research and potential future clinical trials."
        }
    }
}